{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:29:01Z","timestamp":1792985341627,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008129","name":"Helsinn","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s13555-022-00813-y","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T03:20:16Z","timestamp":1665717616000},"page":"2517-2529","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Chlormethine Gel for the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma: In Vitro Release and Permeation Testing"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1600-544X","authenticated-orcid":false,"given":"Claudio","family":"Giuliano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3072-8794","authenticated-orcid":false,"given":"Stefano","family":"Frizzarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0123-8160","authenticated-orcid":false,"given":"Alessandro","family":"Alonzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0346-9587","authenticated-orcid":false,"given":"Virginia","family":"Stimamiglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2985-9639","authenticated-orcid":false,"given":"Pablo L.","family":"Ortiz-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"key":"813_CR1","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.2147\/CMAR.S138661","volume":"11","author":"D Denis","year":"2019","unstructured":"Denis D, Beneton N, Laribi K, et\u00a0al. Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel. Cancer Manag Res. 2019;11:2241\u201351.","journal-title":"Cancer Manag Res"},{"issue":"16","key":"813_CR2","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","volume":"133","author":"R Willemze","year":"2019","unstructured":"Willemze R, Cerroni L, Kempf W, et\u00a0al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703\u201314.","journal-title":"Blood"},{"issue":"Suppl 1","key":"813_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/hon.2850","volume":"39","author":"W Kempf","year":"2021","unstructured":"Kempf W, Mitteldorf C. Cutaneous T-cell lymphomas-an update 2021. Hematol Oncol. 2021;39(Suppl 1):46\u201351.","journal-title":"Hematol Oncol"},{"issue":"1","key":"813_CR4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.33590\/emjhematol\/10313097","volume":"6","author":"J Scarisbrick","year":"2018","unstructured":"Scarisbrick J. Staging of mycosis fungoides and S\u00e9zary syndrome: time for an update? EMJ Hematology. 2018;6(1):92\u2013100.","journal-title":"EMJ Hematology"},{"key":"813_CR5","unstructured":"National Comprehensive Cancer Network. Primary cutaneous lymphomas (version 2.2022). 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/primary_cutaneous.pdf. Accessed 27 July 2022."},{"key":"813_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","volume":"77","author":"F Trautinger","year":"2017","unstructured":"Trautinger F, Eder J, Assaf C, et\u00a0al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/Sezary syndrome - Update 2017. Eur J Cancer. 2017;77:57\u201374.","journal-title":"Eur J Cancer"},{"issue":"Suppl 4","key":"813_CR7","doi-asserted-by":"publisher","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","volume":"29","author":"R Willemze","year":"2018","unstructured":"Willemze R, Hodak E, Zinzani PL, et\u00a0al. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv30\u201340.","journal-title":"Ann Oncol"},{"key":"813_CR8","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3389\/fonc.2019.00260","volume":"9","author":"ES Tarabadkar","year":"2019","unstructured":"Tarabadkar ES, Shinohara MM. Skin directed therapy in cutaneous T-cell lymphoma. Front Oncol. 2019;9:260.","journal-title":"Front Oncol"},{"issue":"6","key":"813_CR9","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1021\/pr200042u","volume":"10","author":"ED Michaelson-Richie","year":"2011","unstructured":"Michaelson-Richie ED, Ming X, Codreanu SG, et\u00a0al. Mechlorethamine-induced DNA-protein cross-linking in human fibrosarcoma (HT1080) cells. J Proteome Res. 2011;10(6):2785\u201396.","journal-title":"J Proteome Res"},{"key":"813_CR10","first-page":"9","volume-title":"Molecular therapies of cancer","author":"GF Weber","year":"2014","unstructured":"Weber GF. DNA damaging drugs. In: Molecular therapies of cancer. Cham: Springer; 2014. p. 9\u2013112."},{"issue":"1","key":"813_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2021.100069","volume":"2","author":"YT Chang","year":"2021","unstructured":"Chang YT, Ignatova D, Hoetzenecker W, et\u00a0al. Increased chlormethine-induced DNA double-stranded breaks in malignant T-cells from mycosis fungoides skin lesions. JID Innov. 2021;2(1): 100069.","journal-title":"JID Innov"},{"issue":"4","key":"813_CR12","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s13555-021-00539-3","volume":"11","author":"LJ Geskin","year":"2021","unstructured":"Geskin LJ, Bagot M, Hodak E, et\u00a0al. Chlormethine gel for the treatment of skin lesions in all stages of mycosis fungoides cutaneous T-cell lymphoma: a narrative review and international experience. Dermatol Therapy. 2021;11(4):1085\u2013106.","journal-title":"Dermatol Therapy"},{"issue":"2","key":"813_CR13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3949\/ccjm.50.2.97","volume":"50","author":"EC Vonderheid","year":"1983","unstructured":"Vonderheid EC, Van Scott EJ. Commentary and update: topical chemotherapy with mechlorethamine for mycosis fungoides. Cleve Clin Q. 1983;50(2):97\u2013100.","journal-title":"Cleve Clin Q"},{"key":"813_CR14","unstructured":"ChemEurope.com. Mechlorethamine. https:\/\/www.chemeurope.com\/en\/encyclopedia\/Mechlorethamine.html. Accessed 27 July 2022."},{"key":"813_CR15","unstructured":"DRUGBANK Online. Mechlorethamine. https:\/\/go.drugbank.com\/drugs\/DB00888. Accessed 27 July 2022."},{"key":"813_CR16","volume-title":"IARC","author":"International Agency for Research on Cancer","year":"2012","unstructured":"International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans, no. 100A. In: IARC. Lyon: Pharmaceuticals; 2012."},{"key":"813_CR17","unstructured":"European Medicines Agency. Assessment report: LEDAGA. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/ledaga-epar-public-assessment-report_en.pdf. Accessed 27 July 2022."},{"issue":"2","key":"813_CR18","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/archderm.139.2.165","volume":"139","author":"YH Kim","year":"2003","unstructured":"Kim YH, Martinez G, Varghese A, et\u00a0al. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford Experience. Arch Dermatol. 2003;139(2):165\u201373.","journal-title":"Arch Dermatol"},{"issue":"2","key":"813_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1468-3083.2011.04433.x","volume":"27","author":"LM Lindahl","year":"2013","unstructured":"Lindahl LM, Fenger-Gron M, Iversen L. Topical nitrogen mustard therapy in patients with mycosis fungoides or parapsoriasis. J Eur Acad Dermatol Venereol. 2013;27(2):163\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"813_CR20","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.jid.2020.12.009","volume":"141","author":"C Querfeld","year":"2021","unstructured":"Querfeld C, Geskin LJ, Kim EJ, et\u00a0al. Lack of systemic absorption of topical mechlorethamine gel in patients with mycosis fungoides cutaneous T-cell lymphoma. J Investig Dermatol. 2021;141(6):1601\u20134.","journal-title":"J Investig Dermatol"},{"issue":"1\u20132","key":"813_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ijpharm.2008.06.016","volume":"362","author":"WA Ritschel","year":"2008","unstructured":"Ritschel WA, Ye W, Buhse L, et\u00a0al. Stability of the nitrogen mustard mechlorethamine in novel formulations for dermatological use. Int J Pharm. 2008;362(1\u20132):67\u201373.","journal-title":"Int J Pharm"},{"key":"813_CR22","doi-asserted-by":"publisher","first-page":"9093","DOI":"10.1200\/jco.2014.32.15_suppl.9093","volume":"32","author":"YH Kim","year":"2014","unstructured":"Kim YH, Duvic M, Guitart J, et\u00a0al. Efficacy and safety of mechlorethamine (MCH) 0.04% gel in mycosis fungoides (MF) after treatment with topical MCH 0.02%. J Clin Oncol. 2014;32:9093.","journal-title":"J Clin Oncol"},{"issue":"3","key":"813_CR23","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40257-021-00591-x","volume":"22","author":"EJ Kim","year":"2021","unstructured":"Kim EJ, Guitart J, Querfeld C, et\u00a0al. The PROVe study: US real-world experience with chlormethine\/mechlorethamine gel in combination with other therapies for patients with mycosis fungoides cutaneous T-cell lymphoma. Am J Clin Dermatol. 2021;22(3):407\u201314.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"813_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","volume":"149","author":"SR Lessin","year":"2013","unstructured":"Lessin SR, Duvic M, Guitart J, et\u00a0al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013;149(1):25\u201332.","journal-title":"JAMA Dermatol"},{"issue":"10","key":"813_CR25","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1517\/17425247.2012.711756","volume":"9","author":"X Tan","year":"2012","unstructured":"Tan X, Feldman SR, Chang J, et\u00a0al. Topical drug delivery systems in dermatology: a review of patient adherence issues. Expert Opin Drug Deliv. 2012;9(10):1263\u201371.","journal-title":"Expert Opin Drug Deliv"},{"key":"813_CR26","unstructured":"Helsinn Therapeutics. VALCHLOR (mechlorethamine) [package insert]. U.S. Food and Drug Administration website. Revised January 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/202317s009lbl.pdf. Accessed 27 July 2022."},{"key":"813_CR27","unstructured":"Helsinn Therapeutics. LEDAGA (mechlorethamine) [summary of product characteristics]. European Medicines Agency website. Revised January 24, 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ledaga. Accessed 27 July 2022."},{"key":"813_CR28","unstructured":"U.S. Food and Drug Administration. Scale-up and postapproval changes: chemistry, manufacturing, and controls; in vitro release testing and in vivo bioequivalence documentation. Center for Drug Evaluation and Research. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/supac-ss-nonsterile-semisolid-dosage-forms-scale-and-post-approval-changes-chemistry-manufacturing. Accessed 27 July 2022."},{"issue":"15","key":"813_CR29","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1021\/ac00015a004","volume":"63","author":"J Cummings","year":"1991","unstructured":"Cummings J, MacLellan A, Smyth JF, et\u00a0al. Determination of reactive nitrogen mustard anticancer drugs in plasma by high-performance liquid chromatography using derivatization. Anal Chem. 1991;63(15):1514\u20139.","journal-title":"Anal Chem"},{"issue":"20","key":"813_CR30","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","journal-title":"JAMA"},{"issue":"6","key":"813_CR31","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jaad.2005.08.057","volume":"53","author":"N Pimpinelli","year":"2005","unstructured":"Pimpinelli N, Olsen EA, Santucci M, et\u00a0al. Defining early mycosis fungoides. J Am Acad Dermatol. 2005;53(6):1053\u201363.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"813_CR32","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1007\/s12325-021-01721-x","volume":"38","author":"K Lampadaki","year":"2021","unstructured":"Lampadaki K, Koumourtzis M, Karagianni F, et\u00a0al. Chlormethine gel in combination with other therapies in the treatment of patients with mycosis fungoides cutaneous T-cell lymphoma: three case reports. Adv Ther. 2021;38(6):3455\u201364.","journal-title":"Adv Ther"},{"issue":"4","key":"813_CR33","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1377\/hlthaff.2014.1160","volume":"34","author":"JS Ross","year":"2015","unstructured":"Ross JS, Dzara K, Downing NS. Efficacy and safety concerns are important reasons why the FDA requires multiple reviews before approval of new drugs. Health Aff. 2015;34(4):681\u20138.","journal-title":"Health Aff"},{"key":"813_CR34","unstructured":"International Society for Pharmaceutical Engineering. Good Manufacturing Practice (GMP) Resources. https:\/\/ispe.org\/initiatives\/regulatory-resources\/gmp. Accessed 27 July 2022."},{"key":"813_CR35","unstructured":"U.S. Food and Drug Administration. Facts About the Current Good Manufacturing Practices (CGMPs). https:\/\/www.fda.gov\/drugs\/pharmaceutical-quality-resources\/facts-about-current-good-manufacturing-practices-cgmps. Accessed 27 July 2022."},{"issue":"1","key":"813_CR36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.18773\/austprescr.2017.001","volume":"40","author":"JR Falconer","year":"2017","unstructured":"Falconer JR, Steadman KJ. Extemporaneously compounded medicines. Aust Prescr. 2017;40(1):5\u20138.","journal-title":"Aust Prescr"},{"issue":"1","key":"813_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40268-013-0005-9","volume":"13","author":"J Gudeman","year":"2013","unstructured":"Gudeman J, Jozwiakowski M, Chollet J, et\u00a0al. Potential risks of pharmacy compounding. Drugs R&D. 2013;13(1):1\u20138.","journal-title":"Drugs R&D"},{"key":"813_CR38","unstructured":"U.S. Food and Drug Administration. Compounding laws and policies. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/supac-ss-nonsterile-semisolid-dosage-forms-scale-and-post-approval-changes-chemistry-manufacturing. Accessed 27 July 2022."},{"issue":"1","key":"813_CR39","doi-asserted-by":"publisher","first-page":"252","DOI":"10.15520\/ijmhs.v9i1.2420","volume":"9","author":"AK Mohiuddin","year":"2019","unstructured":"Mohiuddin AK. Extemporaneous compounding: cautions, controversies and convenience. Innov J Med Health Sci. 2019;9(1):252\u201364.","journal-title":"Innov J Med Health Sci"},{"issue":"3","key":"813_CR40","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1529-8019.2009.01235.x","volume":"22","author":"L Krochmal","year":"2009","unstructured":"Krochmal L. Considerations before choosing (extemporaneously) compounded products. Dermatol Ther. 2009;22(3):225\u20138.","journal-title":"Dermatol Ther"},{"issue":"16","key":"813_CR41","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.2165\/11640850-000000000-00000","volume":"72","author":"S Sellers","year":"2012","unstructured":"Sellers S, Utian WH. Pharmacy compounding primer for physicians: prescriber beware. Drugs. 2012;72(16):2043\u201350.","journal-title":"Drugs"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00813-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-022-00813-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00813-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T08:45:16Z","timestamp":1678265116000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-022-00813-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["813"],"URL":"https:\/\/doi.org\/10.1007\/s13555-022-00813-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]},"assertion":[{"value":"7 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}